Compare LITM & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITM | NTRB |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Industrial Specialties |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.7M | 57.0M |
| IPO Year | N/A | N/A |
| Metric | LITM | NTRB |
|---|---|---|
| Price | $2.91 | $4.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 524.6K | 15.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.34 | $3.96 |
| 52 Week High | $10.38 | $11.68 |
| Indicator | LITM | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 43.33 |
| Support Level | $2.91 | $4.06 |
| Resistance Level | $3.12 | $4.49 |
| Average True Range (ATR) | 0.30 | 0.25 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 22.73 | 26.47 |
Snow Lake Resources Ltd is a Canadian nuclear fuel cycle and critical minerals company with a portfolio of U.S.-focused uranium projects, including the Pine Ridge Uranium Project in the Powder River Basin in Wyoming. The company also holds exploration-stage critical minerals projects including the Snow Lake Lithium Project, Shatford Lake Lithium Project, and Engo Valley Uranium Project in Manitoba, Canada, and Namibia. Snow Lake has investments in companies with critical minerals assets, including rare earths and lithium in North America. The primary commercial use for U3O8 is as fuel for nuclear power plants to generate electricity.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.